BIOTE (BTMD) Q1 2025: Dietary Supplement Revenue Jumps 26% as Sales Force Realignment Targets Clinic Growth
BTMD’s Q1 saw a decisive pivot toward growth, with dietary supplements outpacing expectations and a 25% sales force expansion aimed at reversing procedure softness. A newly announced commercial realignment focuses on accelerating new clinic wins and deepening top-tier provider engagement, but investors face a transition year as execution risk remains elevated. Management maintains full-year guidance, betting on organizational overhaul to restore momentum.
Summary
- Sales Force Restructuring Signals Growth Focus: Commercial team realigned, shifting support staff to sales roles and increasing field sales capacity by 25%.
- Dietary Supplements Offset Procedure Weakness: E-commerce channel drove strong supplement growth, helping counter procedure volume headwinds.
- Transition Year Execution Risk: Management expects impact from new initiatives to materialize gradually, keeping 2025 as a reset period.
Performance Analysis
BTMD’s Q1 2025 performance was marked by a clear divergence between its two core revenue streams. Dietary supplement revenue surged 25.5% year-over-year, propelled by robust e-commerce performance and the ongoing ramp-up of the Amazon channel, while procedure revenue declined 3.6% due to lower commercial effectiveness and a slowdown in new clinic additions. This mix shift, combined with cost savings from vertical integration of the 503B manufacturing facility, drove a 300 basis point improvement in gross margin to 74.3%.
Adjusted EBITDA fell 3.4%, as increased investment in sales and marketing to drive future growth outweighed margin gains. SG&A rose 16.4% from the prior year, reflecting these investments, but was down sharply from Q4 2024 as legal and employee-related costs normalized. Cash flow from operations was positive, and the balance sheet remains healthy with $41.7 million in cash.
- Supplement Channel Strength: E-commerce and Amazon onboarding drove outperformance in supplements, with no one-time items inflating results.
- Procedure Volume Drag: New clinic starts and base business volumes both suffered from the lingering effects of last year’s clinical decision support software (CDSS) rollout.
- Margin Expansion: Vertical integration and cost management lifted gross profit, though mix and product cycles remain quarter-to-quarter variables.
The quarter’s results highlight BTMD’s ability to diversify revenue streams, but also expose the fragility of its procedure-driven annuity model when new clinic momentum falters.
Executive Commentary
"We are focused on three major objectives. First, we intend to accelerate new provider wins to further expand our nationwide network. Second, we intend to strengthen relationships with our existing top tier providers. And third, we intend to improve our financial performance by strengthening accountability and improving consistency and discipline throughout the commercial organization."
Brett Christensen, Chief Executive Officer
"Dietary supplement revenue increased 25.5% to $9.3 million, primarily driven by the growth of our e-commerce channel. We continue to expect solid growth this year from our dietary supplements business."
Bob Peterson, Chief Financial Officer
Strategic Positioning
1. Sales Force Realignment and Commercial Focus
BTMD’s most significant move this quarter was the realignment of its commercial organization, shifting nearly 20 support staff into sales roles and increasing the field sales force by 25%. This move aims to reignite new clinic additions, a critical lever in the company’s annuity-style procedure revenue model, and address the commercial distraction caused by last year’s CDSS launch. The company is also restructuring compensation plans to reward growth over maintenance, signaling a culture shift toward aggressive expansion.
2. Vertical Integration and Margin Discipline
The company’s vertical integration of its 503B manufacturing facility continues to deliver gross margin benefits, now visible in the 300 basis point margin expansion. Management describes this integration as being in the “fourth inning,” with further conversion and expansion planned for the remainder of the year. The focus remains on scaling without disrupting clinic operations, balancing near-term margin gains with long-term operational stability.
3. Diversification via Supplements and E-Commerce
Dietary supplements, particularly through the e-commerce channel, have become a reliable growth engine, offsetting core procedure volatility. Management expects continued strength, though growth rates are expected to moderate as year-over-year comparisons toughen in the second half due to the prior year’s Amazon onboarding. This channel diversification helps reduce dependence on the more cyclical procedure business, providing a buffer against operational setbacks.
Key Considerations
BTMD’s Q1 2025 is defined by a deliberate shift from stabilization to growth, but the impact of commercial changes will not be immediate. Investors should monitor several critical factors as the year unfolds:
- Clinic Pipeline Rebuild: The success of the sales force expansion and realignment will be measured by the pace of new clinic additions and the return to positive procedure revenue growth.
- Supplement Channel Sustainability: Continued e-commerce outperformance is expected, but growth rates will likely normalize as tougher comps set in later this year.
- Margin Volatility: While vertical integration is boosting gross margins, product mix and the pace of conversion could introduce quarter-to-quarter swings.
- Execution Risk in Transition: Management acknowledges a transition year, with early indicators like training volumes and new clinic onboarding being leading signals for future reported revenue.
Risks
BTMD’s annuity revenue model is highly sensitive to new clinic momentum, and the company faces execution risk as it attempts to rapidly overhaul its commercial organization. The impact of sales force realignment may lag, and any further disruption from ongoing integration or competitive pricing could pressure both top-line and margins. While management sees no major tariff exposure, industry-wide cost volatility and potential attrition upticks remain watchpoints. The company’s full-year guide assumes a return to growth in procedures, which is not yet visible in current trends.
Forward Outlook
For Q2 2025, BTMD guided to:
- Revenue and adjusted EBITDA similar to or slightly higher than Q2 2024
- One-time restructuring charge of $0.6–0.8 million
For full-year 2025, management maintained guidance:
- Revenue: $202–208 million
- Adjusted EBITDA: $59–64 million
Management emphasized that 2025 is a transition year, with expectations that the benefits of commercial restructuring and sales force expansion will begin to materialize in the second half. Risks to procedure revenue growth remain, but confidence in the overall revenue and EBITDA guide is underpinned by supplement strength and operational discipline.
Takeaways
BTMD is betting on a commercial turnaround and diversified revenue streams to restore growth, but the path is not without risk.
- Commercial Overhaul Underway: The 25% sales force increase and alignment to growth signals a bold pivot, but results will take time to show in reported numbers.
- Supplement Growth Provides Cushion: E-commerce-driven supplement sales are helping to offset core procedure weakness, though growth rates will moderate against tougher comps.
- Execution in Focus for H2: Investors should watch for early signs of new clinic momentum and sustained margin expansion as leading indicators of a successful transition.
Conclusion
BTMD’s Q1 2025 underscores a company in active transformation, with management making aggressive moves to rebuild commercial momentum and diversify revenue. The supplement business is emerging as a bright spot, but the success of the sales force overhaul and new clinic ramp will determine whether the company can return to sustainable growth. Investors face a transition year with execution risk, but a clear roadmap for improvement is in place.
Industry Read-Through
BTMD’s results highlight the growing importance of diversified revenue streams in the therapeutic wellness and hormone optimization sector. The surge in supplement e-commerce sales and the operational leverage from vertical integration are themes likely to resonate across the sector. The company’s experience with commercial disruption from software rollouts and the need for aggressive sales force realignment offer cautionary lessons for peers relying on annuity-style procedure revenue. As clinics and providers expect more integrated support, competitors may need to invest in both technology and sales infrastructure to maintain share.